Zoetis (ZTS) Competitors and Alternatives 2024 (2024)

Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.8%. Zoetis pays out 33.3% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

See Also

Zoetis Named One of the World’s Most Ethical Companies by EthisphereAbout Zoetis | ZoetisDoes Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?Zoetis History: Founding, Timeline, and Milestones - Zippia

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$8.54B	9.08	$2.34B	$5.19	32.77
Bristol-Myers Squibb	$45.01B	1.86	$8.03B	-$3.10	-13.30

In the previous week, Bristol-Myers Squibb had 18 more articles in the media than Zoetis. MarketBeat recorded 36 mentions for Bristol-Myers Squibb and 18 mentions for Zoetis. Zoetis' average media sentiment score of 0.57 beat Bristol-Myers Squibb's score of 0.54 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol-Myers Squibb	14 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

Zoetis presently has a consensus price target of $211.75, indicating a potential upside of 24.51%. Bristol-Myers Squibb has a consensus price target of $60.00, indicating a potential upside of 45.49%. Given Bristol-Myers Squibb's higher possible upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bristol-Myers Squibb	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Bristol-Myers Squibb received 181 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.82% of users gave Zoetis an outperform vote while only 66.89% of users gave Bristol-Myers Squibb an outperform vote.

Company	Underperform	Outperform
Zoetis	Outperform Votes 898 77.82%	Underperform Votes 256 22.18%
Bristol-Myers Squibb	Outperform Votes 1079 66.89%	Underperform Votes 534 33.11%

Zoetis has a net margin of 27.38% compared to Bristol-Myers Squibb's net margin of -13.50%. Zoetis' return on equity of 50.34% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.38%	50.34%	17.59%
Bristol-Myers Squibb	-13.50%	8.83%	2.50%

See Also

Zoetis's stock falls 8% after report that its arthritis shots may have sickened pets

Summary

Zoetis beats Bristol-Myers Squibb on 13 of the 20 factors compared between the two stocks.

Email Address